Among proteomics experts, however, a split has emerged between those who believe protein profiling patterns, rather than proteins themselves, are important indicators of disease, and those who believe that the proteins need to be identified before they can be useful clinically. Predicant Biosciences is taking the side of the former group, and, supported by a top-notch group of scientists and venture capitalists, is developing an integrated system it hopes will move the field forward.
201 Gateway Boulevard
South San Francisco, CA 94080
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
In this week's episode: Sanofi’s Vicebio buy; Sarepta halts US Elevidys shipments; Novartis warning over Europe; US CRL for Genentech’s Columvi; and an interview with Novavax.
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.